ECSP19011216A - Inhibidores de piridopyrimdinona cdk2/4/6 - Google Patents

Inhibidores de piridopyrimdinona cdk2/4/6

Info

Publication number
ECSP19011216A
ECSP19011216A ECSENADI201911216A ECDI201911216A ECSP19011216A EC SP19011216 A ECSP19011216 A EC SP19011216A EC SENADI201911216 A ECSENADI201911216 A EC SENADI201911216A EC DI201911216 A ECDI201911216 A EC DI201911216A EC SP19011216 A ECSP19011216 A EC SP19011216A
Authority
EC
Ecuador
Prior art keywords
pyridopyrimdinone
cdk2
inhibitors
compounds
salts
Prior art date
Application number
ECSENADI201911216A
Other languages
English (en)
Inventor
Alicia Ornelas Martha
Krishnan Nair Sajiv
Ninkovic Sacha
Chen Ping
Daniel Freeman-Cook Kevin
Nagata Asako
Yuanjin Rui Eugene
Carl BEHENNA Douglas
Jalaie Mehran
Louise Palmer Cynthia
Louis Hoffman Robert
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of ECSP19011216A publication Critical patent/ECSP19011216A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Esta invención se relaciona con compuestos de la Fórmula general (I) (I), y sales farmacéuticamente aceptables de los mismos, en los cuales R1, R2, R¬2A, R2B, R3, R4, R5A, R5B, R6, R7, R8, R9, p, q y r son como se definen en la presente, a composiciones farmacéuticas que comprenden tales compuestos y sales, y métodos para utilizar tales compuestos, sales y composiciones para el tratamiento de crecimiento celular anormal, incluyendo cáncer.
ECSENADI201911216A 2016-08-15 2019-02-14 Inhibidores de piridopyrimdinona cdk2/4/6 ECSP19011216A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662371602P 2016-08-15 2016-08-15
US201762533347P 2017-07-17 2017-07-17

Publications (1)

Publication Number Publication Date
ECSP19011216A true ECSP19011216A (es) 2019-03-29

Family

ID=59631834

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI201911216A ECSP19011216A (es) 2016-08-15 2019-02-14 Inhibidores de piridopyrimdinona cdk2/4/6

Country Status (43)

Country Link
US (4) US10233188B2 (es)
EP (1) EP3497103B1 (es)
JP (1) JP6563623B1 (es)
KR (1) KR102236605B1 (es)
CN (2) CN109803968A (es)
AU (1) AU2017311645B2 (es)
BR (1) BR112019002610A2 (es)
CA (1) CA2975033C (es)
CL (1) CL2019000368A1 (es)
CO (1) CO2019001240A2 (es)
CR (1) CR20190062A (es)
CU (1) CU24522B1 (es)
CY (1) CY1124206T1 (es)
DK (1) DK3497103T3 (es)
DO (1) DOP2019000030A (es)
EC (1) ECSP19011216A (es)
ES (1) ES2876411T3 (es)
GE (1) GEP20217234B (es)
HR (1) HRP20210871T1 (es)
HU (1) HUE055978T2 (es)
IL (1) IL264687B (es)
LT (1) LT3497103T (es)
MA (1) MA45920B1 (es)
MD (1) MD3497103T2 (es)
MX (1) MX389597B (es)
MY (1) MY198534A (es)
NI (1) NI201900013A (es)
NZ (1) NZ750410A (es)
PE (1) PE20190475A1 (es)
PH (1) PH12019500329A1 (es)
PL (1) PL3497103T3 (es)
PT (1) PT3497103T (es)
RS (1) RS61934B1 (es)
RU (1) RU2726115C1 (es)
SG (1) SG11201900799XA (es)
SI (1) SI3497103T1 (es)
SV (1) SV2019005836A (es)
TN (1) TN2019000039A1 (es)
TW (1) TWI663169B (es)
UA (1) UA124804C2 (es)
UY (1) UY37352A (es)
WO (1) WO2018033815A1 (es)
ZA (1) ZA201900716B (es)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3497103T (pt) * 2016-08-15 2021-06-17 Pfizer Inibidores de piridopirimidinona cdk2/4/6
JP6952747B2 (ja) 2018-09-18 2021-10-20 ファイザー・インク がん処置のためのＴＧＦβ阻害剤およびＣＤＫ阻害剤の組合せ
JP2020097562A (ja) 2018-09-25 2020-06-25 ファイザー・インク ピリド［２，３−ｄ］ピリミジン−７（８ｈ）−オンの合成
US11066404B2 (en) 2018-10-11 2021-07-20 Incyte Corporation Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
US20220040324A1 (en) 2018-12-21 2022-02-10 Daiichi Sankyo Company, Limited Combination of antibody-drug conjugate and kinase inhibitor
AU2020209500B2 (en) * 2019-01-17 2022-08-25 Pfizer Inc. Crystalline form of a CDK inhibitor
US11384083B2 (en) 2019-02-15 2022-07-12 Incyte Corporation Substituted spiro[cyclopropane-1,5′-pyrrolo[2,3-d]pyrimidin]-6′(7′h)-ones as CDK2 inhibitors
PH12021551976A1 (en) * 2019-02-15 2022-07-04 Incyte Corp Cyclin-dependent kinase 2 biomarkers and uses thereof
TW202100520A (zh) 2019-03-05 2021-01-01 美商英塞特公司 作為cdk2 抑制劑之吡唑基嘧啶基胺化合物
WO2020205560A1 (en) 2019-03-29 2020-10-08 Incyte Corporation Sulfonylamide compounds as cdk2 inhibitors
JP2022529930A (ja) * 2019-04-19 2022-06-27 ファイザー・インク Ｐａｈを処置するための抗増殖薬
WO2020223469A1 (en) 2019-05-01 2020-11-05 Incyte Corporation N-(1-(methylsulfonyl)piperidin-4-yl)-4,5-di hydro-1h-imidazo[4,5-h]quinazolin-8-amine derivatives and related compounds as cyclin-dependent kinase 2 (cdk2) inhibitors for treating cancer
US11447494B2 (en) 2019-05-01 2022-09-20 Incyte Corporation Tricyclic amine compounds as CDK2 inhibitors
WO2020239558A1 (en) 2019-05-24 2020-12-03 Pfizer Inc. Combination therapies using cdk inhibitors
CA3141452A1 (en) * 2019-05-24 2020-12-03 Pfizer Inc. Combination therapies using cdk inhibitors
WO2021014360A1 (en) 2019-07-23 2021-01-28 Pfizer Inc. Oral modified release dosage forms
CA3150681A1 (en) 2019-08-14 2021-02-18 Incyte Corporation Imidazolyl pyrimidinylamine compounds as cdk2 inhibitors
US11851426B2 (en) * 2019-10-11 2023-12-26 Incyte Corporation Bicyclic amines as CDK2 inhibitors
JP7667147B2 (ja) * 2019-10-17 2025-04-22 シーセン ファーマシューティカル カンパニー リミテッド Ｃｄｋ２／４／６三重阻害剤としてのアミノピリミジン化合物
CA3164623A1 (en) 2019-12-17 2021-06-24 Pfizer Inc. Antibodies specific for cd47, pd-l1, and uses thereof
EP4110782A1 (en) * 2020-02-28 2023-01-04 Fochon Biosciences, Ltd. Compounds as cdk2/4/6 inhibitors
TW202146017A (zh) 2020-03-05 2021-12-16 美商輝瑞股份有限公司 間變性淋巴瘤激酶抑制劑及周期蛋白依賴型激酶抑制劑之組合
JP2021167301A (ja) 2020-04-08 2021-10-21 ファイザー・インク Ｃｄｋ２阻害剤に対する腫瘍適応を抑制するためのｃｄｋ４／６およびｃｄｋ２阻害剤による同時処置
CN113773315A (zh) * 2020-06-10 2021-12-10 无锡佰翱得生物科学有限公司 细胞周期蛋白依赖性激酶2（cdk2）高选择性氘代抑制剂
WO2021254384A1 (zh) * 2020-06-17 2021-12-23 微境生物医药科技(上海)有限公司 新型吡啶并[2，3-d]嘧啶-7(8H)-酮衍生物
WO2022015670A1 (en) * 2020-07-14 2022-01-20 Nikang Therapeutics, Inc. Pyrido[2,3-d]pyrimidin-7(8h)-one derivatives as cyclin-dependent kinase 2 inhibitors
WO2022018667A1 (en) 2020-07-24 2022-01-27 Pfizer Inc. Combination therapies using cdk2 and cdc25a inhibitors
AU2021345531B2 (en) 2020-09-15 2024-02-29 Pfizer Inc. Solid forms of a CDK4 inhibitor
WO2022113003A1 (en) 2020-11-27 2022-06-02 Rhizen Pharmaceuticals Ag Cdk inhibitors
WO2022140472A1 (en) * 2020-12-22 2022-06-30 Nikang Therapeutics, Inc. Compounds for degrading cyclin-dependent kinase 2 via ubiquitin proteosome pathway
WO2022149057A1 (en) 2021-01-05 2022-07-14 Rhizen Pharmaceuticals Ag Cdk inhibitors
CN117858879A (zh) * 2021-01-15 2024-04-09 南京再明医药有限公司 Cdk2/4/6抑制剂及其制备方法和应用
KR20240020735A (ko) 2021-05-07 2024-02-15 카이메라 쎄라퓨틱스 인코포레이티드 Cdk2 분해제 및 그 용도
AU2022289202B2 (en) * 2021-06-09 2025-09-25 Tyk Medicines (Zhengzhou) , Inc. Compound as cdk kinase inhibitor and use thereof
US11981671B2 (en) 2021-06-21 2024-05-14 Incyte Corporation Bicyclic pyrazolyl amines as CDK2 inhibitors
WO2023281413A1 (en) 2021-07-09 2023-01-12 Pfizer Inc. Methods and dosing regimens comprising pf-06873600 for the treatment of cancer
CN116390921A (zh) * 2021-09-29 2023-07-04 中国医药研究开发中心有限公司 具有细胞周期蛋白依赖性激酶抑制活性的杂环化合物及其制备方法和医药用途
WO2023092104A1 (en) * 2021-11-18 2023-05-25 Onconova Therapeutics, Inc. Methods and compositions for treating cancer
US11976073B2 (en) 2021-12-10 2024-05-07 Incyte Corporation Bicyclic amines as CDK2 inhibitors
US20250049802A1 (en) 2021-12-14 2025-02-13 Pfizer Inc. Combination therapies and uses for treating cancer
WO2023141522A2 (en) * 2022-01-21 2023-07-27 Slap Pharmaceuticals Llc Multicyclic compounds
CA3249870A1 (en) * 2022-01-25 2023-08-03 Kinnate Biopharma Inc. CDK4/6 KINASE INHIBITORS
AU2023289896A1 (en) * 2022-06-22 2024-12-05 Nikang Therapeutics, Inc. Bifunctional compounds containing pyrido[2,3-djpyrimidin-7(8h)-one derivatives for degrading cyclin-dependent kinase 2 via ubiquitin proteasome pathway
US20240174665A1 (en) * 2022-08-19 2024-05-30 Kymera Therapeutics, Inc. Cdk2 inhibitors and uses thereof
CN120379671A (zh) 2022-10-18 2025-07-25 辉瑞公司 用于治疗癌症的化合物
WO2024173766A1 (en) * 2023-02-17 2024-08-22 Differentiated Therapeutics, Inc. Cyclin dependent kinase degraders and methods of use thereof
US20240425521A1 (en) 2023-06-01 2024-12-26 H. Lundbeck A/S Spiromacrocyclic orexin 2 receptor agonists
WO2025175258A1 (en) * 2024-02-17 2025-08-21 Padarn Therapeutics, Inc. Inhibitors of cdk2
WO2025207957A1 (en) * 2024-03-28 2025-10-02 Yale University Small-molecule pi5p4k alpha/beta inhibitors and methods using same
CN120842218A (zh) * 2024-04-26 2025-10-28 郑州同源康医药有限公司 一种嘧啶并氮杂环类化合物的晶型及其制备方法及应用
WO2026024674A1 (en) 2024-07-22 2026-01-29 Genesis Therapeutics, Inc. Methods of treating skp2-associated cancers

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
TW477787B (en) 1996-08-27 2002-03-01 Pfizer Pyrido six-membered nitrogen-containing cyclic ring derivatives having corticotropin releasing factor antagonist activity and pharmaceutical composition containing same
WO1998023613A1 (en) 1996-11-27 1998-06-04 Pfizer Inc. Fused bicyclic pyrimidine derivatives
WO2000035296A1 (en) 1996-11-27 2000-06-22 Wm. Wrigley Jr. Company Improved release of medicament active agents from a chewing gum coating
US6498163B1 (en) * 1997-02-05 2002-12-24 Warner-Lambert Company Pyrido[2,3-D]pyrimidines and 4-aminopyrimidines as inhibitors of cellular proliferation
WO1998033798A2 (en) 1997-02-05 1998-08-06 Warner Lambert Company Pyrido[2,3-d]pyrimidines and 4-amino-pyrimidines as inhibitors of cell proliferation
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
JP2003523358A (ja) * 2000-01-27 2003-08-05 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー 神経変性疾患の治療のためのピリドピリミジノン誘導体
AP2002002643A0 (en) 2000-03-06 2002-12-31 Warner Lambert Co 5-alkylpyrido[2,3-d]pyrimidines tyrosine kinase inhibitors
DE60206363T2 (de) 2001-02-12 2006-07-06 F. Hoffmann-La Roche Ag 6-substituierte pyridopyrimidine
MXPA04005939A (es) 2002-01-22 2005-01-25 Warner Lambert Co 2-(piridin-2-ilamino)-pirido[2,3-d]pirimidin-7-onas.
US7196090B2 (en) * 2002-07-25 2007-03-27 Warner-Lambert Company Kinase inhibitors
US6951769B2 (en) 2003-06-04 2005-10-04 Texas Instruments Incorporated Method for stripping sacrificial layer in MEMS assembly
AU2004255934B2 (en) 2003-07-11 2010-02-25 Warner-Lambert Company Llc Isethionate salt of a selective CDK4 inhibitor
BRPI0507852A (pt) 2004-02-18 2007-07-10 Warner Lambert Co 2-(piridin-3-ilamino)-pirido[2,3-d]pirimidin-7-onas
US20060142312A1 (en) * 2004-12-23 2006-06-29 Pfizer Inc C6-aryl and heteroaryl substituted pyrido[2,3-D] pyrimidin-7-ones
CN102746298A (zh) * 2005-10-07 2012-10-24 埃克塞里艾克西斯公司 PI3Kα的吡啶并嘧啶酮抑制剂
EA016945B1 (ru) * 2005-10-07 2012-08-30 Экселиксис, Инк. ПИРИДОПИРИМИДИНОНОВЫЕ ИНГИБИТОРЫ PI3Kα
BRPI0716880A2 (pt) 2006-09-08 2013-10-15 Pfizer Prod Inc Síntese de 2-(piridin-2-ilamino)-pirido[2,3-d]pirimidin-7-onas
PT2074122E (pt) * 2006-09-15 2011-08-24 Pfizer Prod Inc Compostos de pirido(2,3-d)-pirimidinona e sua utilização como inibidores de pi3
EP1914234A1 (en) * 2006-10-16 2008-04-23 GPC Biotech Inc. Pyrido[2,3-d]pyrimidines and their use as kinase inhibitors
MY150697A (en) * 2007-04-10 2014-02-28 Exelixis Inc Methods of treating cancer using pyridopyrimdinone inhibitors of p13k alpha
CA2719868A1 (en) * 2008-04-29 2009-11-05 F. Hoffmann-La Roche Ag Pyrimidinyl pyridone inhibitors of jnk.
US8557809B2 (en) 2008-08-19 2013-10-15 Array Biopharma Inc. Triazolopyridine compounds as PIM kinase inhibitors
CA2734037A1 (en) 2008-10-22 2010-04-29 F. Hoffmann-La Roche Ag Pyrimidinyl pyridone inhibitors of jnk
WO2013043232A2 (en) * 2011-04-08 2013-03-28 Afraxis, Inc. 8-ethyl-6-(aryl)pyrido [2,3-d]pyrimidin-7(8h) -ones for the treatment of nervous system disorders and cancer
CN103635183A (zh) * 2011-04-29 2014-03-12 埃克塞利希斯股份有限公司 使用pi3k/mtor的吡啶并嘧啶抑制剂来治疗淋巴瘤的方法
TW201306842A (zh) * 2011-06-15 2013-02-16 Exelixis Inc 使用ｐｉ３ｋ／ｍｔｏｒ吡啶並嘧啶酮抑制劑及苯達莫司汀及／或利妥昔單抗治療惡性血液疾病之組合療法
AR088082A1 (es) 2011-10-13 2014-05-07 Lilly Co Eli Moduladores selectivos del receptor androgeno
MX2014010176A (es) * 2012-02-23 2014-11-10 Abbvie Inc Inhibidores de cinasas de piridopirimidinona.
MX386473B (es) 2013-02-21 2025-03-18 Pfizer Formas solidas de un inhibidor de cdk4/6 selectivo
US9321786B2 (en) 2013-03-15 2016-04-26 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
WO2015084936A1 (en) * 2013-12-04 2015-06-11 The Scripps Research Institute Novel compounds as jnk kinase inhibitors
US9734210B2 (en) 2014-07-31 2017-08-15 Linkedin Corporation Personalized search based on searcher interest
CZ201589A3 (cs) * 2015-02-11 2016-08-24 Zentiva, K.S. Pevné formy soli Palbociclibu
PT3497103T (pt) * 2016-08-15 2021-06-17 Pfizer Inibidores de piridopirimidinona cdk2/4/6

Also Published As

Publication number Publication date
PE20190475A1 (es) 2019-04-04
US20200392142A1 (en) 2020-12-17
BR112019002610A2 (pt) 2019-07-02
KR102236605B1 (ko) 2021-04-05
CN114394966A (zh) 2022-04-26
DOP2019000030A (es) 2019-06-30
UY37352A (es) 2018-03-23
MA45920A (fr) 2019-06-19
TW201819383A (zh) 2018-06-01
MA45920B1 (fr) 2021-08-31
US10800783B2 (en) 2020-10-13
CR20190062A (es) 2019-05-22
PH12019500329A1 (en) 2019-10-28
AU2017311645B2 (en) 2021-05-27
CO2019001240A2 (es) 2019-02-19
PL3497103T3 (pl) 2021-10-25
RU2726115C1 (ru) 2020-07-09
JP6563623B1 (ja) 2019-08-21
DK3497103T3 (da) 2021-06-14
WO2018033815A1 (en) 2018-02-22
TN2019000039A1 (en) 2020-07-15
ZA201900716B (en) 2022-03-30
HUE055978T2 (hu) 2022-01-28
US20180044344A1 (en) 2018-02-15
HRP20210871T1 (hr) 2021-07-09
CU24522B1 (es) 2021-06-08
CN114394966B (zh) 2024-10-11
TWI663169B (zh) 2019-06-21
SI3497103T1 (sl) 2021-07-30
CA2975033C (en) 2023-01-24
MY198534A (en) 2023-09-04
PT3497103T (pt) 2021-06-17
NZ750410A (en) 2025-06-27
US20220324872A1 (en) 2022-10-13
CN109803968A (zh) 2019-05-24
ES2876411T3 (es) 2021-11-12
KR20190038915A (ko) 2019-04-09
AU2017311645A1 (en) 2019-02-28
MX389597B (es) 2025-03-20
EP3497103B1 (en) 2021-05-05
MD3497103T2 (ro) 2021-08-31
US20190135817A1 (en) 2019-05-09
NI201900013A (es) 2019-04-08
SV2019005836A (es) 2019-03-19
RS61934B1 (sr) 2021-07-30
CL2019000368A1 (es) 2019-05-10
US10233188B2 (en) 2019-03-19
LT3497103T (lt) 2021-07-26
US11396512B2 (en) 2022-07-26
CU20190010A7 (es) 2019-10-04
JP2019527722A (ja) 2019-10-03
IL264687B (en) 2021-04-29
CA2975033A1 (en) 2018-02-15
EP3497103A1 (en) 2019-06-19
UA124804C2 (uk) 2021-11-24
MX2019001849A (es) 2019-05-09
CY1124206T1 (el) 2022-05-27
GEP20217234B (en) 2021-03-25
SG11201900799XA (en) 2019-02-27

Similar Documents

Publication Publication Date Title
DOP2019000030A (es) Inhibidores de cdk2/4/6
CL2020002748A1 (es) Inhibidores de cinasa dependientes de ciclina
UY38553A (es) Inhibidores de cdk2
MX2022012313A (es) Oxisteroles y metodos de uso de los mismos.
UY38471A (es) Compuestos de azalactam como inhibidores de hpk1
MX2016014547A (es) Compuestos para tratar atrofia muscular espinal.
NI201400107A (es) Compuestos de heterociclilo como inhibidores de mek
CO2017002998A2 (es) Derivados de tetrahidronaftaleno que inhiben la proteína mcl-1
UY37205A (es) Inhibidores de bromodominios
CR20150371A (es) Inhibidores de prmt5 y sus usos
DOP2014000036A (es) Compuestos de piridazinona y su uso como inhibidores daao
MX2016015248A (es) Compuestos imidazo[1,2-a]pirazin-1-il-benzamida para tratar atrofia muscular espinal.
MX2019003724A (es) Oxisteroles sustituidos en c7 y metodos de uso de los mismos.
CO2020004977A2 (es) Compuestos bicíclicos para su uso como inhibidores de la ripi quinasa
CO2019001181A2 (es) Compuestos de heteroarilcarboxamida como inhibidores de ripk2
ECSP16074478A (es) Compuestos novedosos
CL2017000827A1 (es) Inhibidores de aldosterona sintasa
PY1515461A (es) Derivados de Dihidropirrolopirimidina
SV2016005310A (es) Derivados de diheterociclo enlazado a cicloalquilo
ECSP18056196A (es) Derivados de indano
CU20140033A7 (es) Derivados de pirrolopirimidina y purina
ECSP17003149A (es) Compuestos de dihidroisoquinolinona sustituida